Lymphoma, Leukemia & Myeloma Congress

Home
United States
New York, NY
Lymphoma, Leukemia & Myeloma Congress

The premier forum for healthcare professionals who study and manage patients with lymphoma, myeloma

For the past sixteen years, L&M has been the premier forum on the latest advances in lymphoma and myeloma. Over forty internationally-recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials. The Congress features an

interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphatic leukemia, lymphoma and Hodgkin’s disease.

05/12/2026

Your patient has asymptomatic follicular lymphoma. You recommend observation, but newer data is making that default harder to hold without interrogating it.

Dr. Carla Casulo and Dr. John Leonard will debate this head-on: examining risk stratification, patient selection, timing, and whether observation still offers the greatest long-term benefit or whether we're leaving an opportunity on the table.

A common dilemma in practice. A debate worth having.

https://hubs.ly/Q04f93HR0

05/10/2026

Behind every patient outcome is a coordinated effort across the care team.

From inpatient care to long-term management, multidisciplinary collaboration continues to shape progress in hematologic malignancies.

Learn more about upcoming LL&M events: https://hubs.ly/Q04dJx4G0

05/08/2026

BTK inhibitors vs. venetoclax-based fixed-duration regimens

The frontline CLL treatment decision used to be straightforward. It isn’t anymore.

Dr. Farrukh Awan and Dr. John Allan will debate whether time-limited therapy should be the default across risk groups, or whether continuous treatment delivers more sustained disease control for certain patients. They'll examine depth of response, tolerability, resistance patterns, and how to align treatment choice with patient priorities across risk groups.

Learn More About the Debate: https://hubs.ly/Q04f8xcx0

05/07/2026

During Nurses Week, we acknowledge the ongoing impact of oncology and hematology nurses in patient care, education, and treatment management.

Your role is central to advancing care delivery and supporting patients at every stage—reinforcing the importance of staying current with evolving clinical insights.

Explore upcoming opportunities to stay informed: https://hubs.ly/Q04dJtdM0

05/03/2026

High response rates, shifting durability data, and earlier access are pushing CAR T and bispecifics into a conversation that wasn't happening five years ago: whether transplant still belongs in the frontline for eligible patients.

At LL&M Great Debates, Dr. Saad Usmani and Dr. Jonathan Kaufman will go head-to-head on whether immune-based approaches are ready to challenge transplant in earlier lines of care or whether transplant remains the most reliable path to durable remission for eligible patients.

This is one of the field's most consequential debates right now. Come prepared to examine the data and pressure-test your approach alongside your peers.

Join the Debates: https://hubs.ly/Q04f93GZ0

04/28/2026

📣 Meet the Co-Chairs for LL&M Great Debates

Joseph Mikhael, MD, MEd, FRCPC, FACP leads myeloma, Jessica Altman, MD leads leukemia, and John Leonard, MD leads lymphoma. Together with Emeritus Chair Morton Coleman, MD, they’re guiding this year’s program.

The focus isn’t just on new data. It’s on how that data is actually being used in practice, where approaches differ, and how those decisions play out for patients.

Explore the agenda:
https://hubs.ly/Q04dFnQr0

📆 June 27–28, 2026 | New York City
📆 July 25–26, 2026 | Dallas

04/21/2026

Triplet vs quadruplet therapy in multiple myeloma. How are you approaching induction today?

Quadruplet regimens are driving deeper responses and improved outcomes in clinical trials, building on established triplet backbones. But in practice, the decision is more nuanced.

From tolerability and patient selection to risk stratification and long-term treatment goals, applying these regimens requires careful clinical judgment.

“We’re seeing strong data supporting deeper responses with quadruplet regimens. At the same time, applying these approaches in practice requires thoughtful consideration of the individual patient.” — Ruben Niesvizky, MD

At LL&M Congress, leading experts will examine how evolving induction strategies are shaping real-world decision-making in myeloma care.

Join us this October and gain practical insights to guide your treatment approach.

Register now with early bird pricing: https://bit.ly/3O0KTIB

04/17/2026

When do you actually use targeted therapy in AML?

Not “is it effective.”
Not “what do the guidelines say.”

When do you pull the trigger?

FLT3. IDH1/2. Expanding mutation-directed options have made sequencing just as important as selection.

Start early to maximize disease control?
Hold in reserve to extend options over time?

Both strategies show up in real practice. Both have tradeoffs.

At LL&M Great Debates, this question gets pushed where it belongs, into open disagreement.

Dr. Naval Daver and Dr. Aditi Shastri take opposing positions and challenge each other’s approaches, factoring in disease biology, treatment intensity, and how sequencing decisions shape outcomes.

This is the kind of decision that doesn’t resolve cleanly on paper, but still has to be made in clinic.

Explore the full agenda: https://hubs.ly/Q04cBRn90

04/14/2026

Treatment duration in CLL is evolving, and with it, how clinicians are approaching long-term disease management.

From fixed-duration regimens to the growing role of MRD, new strategies are creating more individualized treatment pathways. The opportunity for treatment-free intervals in some patients, alongside continuous therapy for others, is shifting how care decisions are made.

At LL&M Congress, leading experts will break down how emerging data is shaping these approaches in real-world practice.

“CLL treatment continues to evolve, with new strategies allowing us to better tailor therapy to the individual patient by applying data from clinical trials in more personalized ways.” — Richard Furman, MD

Join us this October to gain practical insights you can apply to treatment decisions in your clinic.

Register now with early bird pricing: https://bit.ly/4v1JLFg

04/10/2026

Dr. Anand Patel is joining us for LL&M Great Debates this year and he sent a quick video on why he's looking forward to stepping into the debates.

Hear what debate he'll be taking on!

Learn More: https://hubs.ly/Q04brDmT0

04/07/2026

CAR-T and bispecific antibodies are moving earlier in lymphoma care. The question is no longer if to use them, but how to apply them in practice.

Each approach brings meaningful advantages, along with important clinical considerations, from durability of response and accessibility to toxicity, sequencing, and patient selection.

At LL&M Congress, leading experts are translating emerging data into real-world clinical decision-making.

“We’re seeing both CAR-T and bispecific antibodies used earlier. The focus now is understanding where each fits and how to apply them effectively across clinical scenarios.” — John Leonard, MD

Join the conversation at LL&M Congress this October and gain practical insights to help guide treatment decisions in your practice. Register now at the early bird rate: https://bit.ly/4cgY81c

Address

811 W 7th Avenue
New York, NY

Website

http://www.lymphomaandmyeloma.com/

Alerts

Be the first to know and let us send you an email when Lymphoma, Leukemia & Myeloma Congress posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Lauren Minchen Nutrition
280 Madison Avenue
Dr. Paul Gregory, DDS
57 W 57th Street
Magnus Wellness
16 E 40th Street, Fl 4